Table 5.
Clinicopathological characteristics according to molecular biomarkers in nGGO
EGFR | ALK | P value* | |
---|---|---|---|
N |
119 |
6 |
|
Age |
63.50 ± 9.11 |
60.00 ± 12.05 |
0.571 |
Sex |
M:F = 43:76 |
M:F = 2:4 |
0.889 |
PYR |
5.805 ± 14.426 |
0.750 ± 1.173 |
0.942 |
Pathologic stage |
117† |
6 |
0.001 |
0 |
6 |
0 |
|
IA |
87 |
1 |
|
IB |
18 |
3 |
|
IIA |
1 |
1 |
|
IIB |
2 |
0 |
|
IIIA |
3 |
1 |
|
IIIB |
0 |
0 |
|
Nodal involvement |
5 |
2 |
0.003 |
Histologic invasiveness |
118** |
6 |
0.351 |
AIS |
6 |
0 |
|
MIA |
11 |
0 |
|
IA |
101 |
6 |
|
Maximal diameter |
22.387 ± 9.876 |
33.583 ± 13.736 |
0.032 |
Solid diameter |
11.133 ± 11.229 |
23.217 ± 16.906 |
0.032 |
TDR | 0.702 ± 0.295 | 0.533 ± 0.327 | 0.225 |
*P value: EGFR vs. ALK.
†Data for pathologic stage were unavailable for 2 patients.
**Data for histologic invasiveness were unavailable for 1 patient.